The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: A prospective, multicentre, observational study

Drug Safety

Volumn 35, Issue 7, 2012, Pages 589-598

  Bar Oz, Benjamin ^a   Weber Schoendorfer, Corinna ^b   Berlin, Maya ^c   Clementi, Maurizio ^d   Di Gianantonio, Elena ^d   De Vries, Loes ^e   De Santis, Marco ^f   Merlob, Paul ^c   Stahl, Bracha ^c   Eleftheriou, Giorgio ^g   Maňáková, Eva ^h   Hubičková Heringová, Lucie ^h   Youngster, Ilan ^c   Berkovitch, Matitiahu ^c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Pharmakovigilanzzentrum Embryonaltoxikologie   (Germany)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY OF PADOVA   (Italy)

^e NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^f CATHOLIC UNIVERSITY   (Italy)

^g Centro Antiveleni Tossicologia Clinica   (Italy)

^h CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEPHALOSPORIN; CLARITHROMYCIN; HAIR DYE; LEVOTHYROXINE; MACROLIDE; PARACETAMOL; PENICILLIN G; ROXITHROMYCIN;

ABORTION; ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR MALFORMATION; COMPARATIVE STUDY; CONGENITAL MALFORMATION; CONTROLLED STUDY; CZECH REPUBLIC; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HEALTH CARE PERSONNEL; HEALTH SERVICE; HELICOBACTER INFECTION; HUMAN; ISRAEL; ITALY; LOW BIRTH WEIGHT; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PNEUMONIA; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; TERATOGENICITY; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT INFECTION;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; EUROPE; FEMALE; HUMANS; MACROLIDES; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84862562387     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11630920-000000000-00000     Document Type: Article

References (22)

1. Czeizel AE, RockenbauerM, Sorensen HT, et al. populationbased case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 1999; 13: 531-6 (Pubitemid 30017329)
2. Källén BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003; 17: 255-61 (Pubitemid 36626946)
3. Källén BA, Otterblad Olausson P, et al. Is erythromycin therapy teratogenic in humans? Reprod Toxicol 2005; 20: 209-14 (Pubitemid 40725070)
4. Erythromycin. In: Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation. 8th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2008: 657-9
5. Heikkinen T, Laine K, Neuvonen PJ, et al. The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. Br J Obstet Gynaecol 2000; 107: 770-5 (Pubitemid 30311914)
6. Wilton LV, Pearce GL, Martin RM, et al. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998; 105: 882-9 (Pubitemid 28423505)
7. Azithromycin. In: Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation. 8th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2008: 158-60
8. Clarithromycin. In: Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation. 8th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2008: 379-80
9. Sarkar M, Woodland C, Koren G, et al. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 2006; 6: 18
10. Drinkard CR, Shatin D, Clouse J. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol Drug Saf 2000; 9: 549-56 (Pubitemid 32294102)
11. Einarson A, Phillips E, Mawji F, et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 1998; 15: 523-5 (Pubitemid 29017981)
12. Bar-Oz B, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after gestational exposure to the new macrolides: a prospective multi-center observational study. Eur J Obstet Gynecol Reprod Biol 2008; 141: 31-4
13. Chun JY, Han JY, Ahn HK, et al. Fetal outcome following roxithromycin exposure in early pregnancy. J Matern Fetal Neonatal Med 2006; 19: 189-92
14. Czeizel AE, Rockenbauer M, Olsen J, et al. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol Scand 2000; 79: 234-7 (Pubitemid 30119799)
15. Paulus W, Karl S, Frank S. Does roxithromycin affect embryo development? Reprod Toxicol 2005; 20: 477
16. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006; 38: 90-6 (Pubitemid 43882311)
17. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2004. Natl Vital Stat Rep 2006; 55: 1-101
18. Centers for Disease Control and Prevention. Metropolitan Atlanta Congenital Defects Program coding manual [online]. Available from URL: http://www.cdc.gov/ncbddd/bd/macdp.htm [Accessed 2012 May 10]
19. Crider KS, Cleves MA, Reefhuis J, et al. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med 2009; 163: 978-85
20. Koren G, Bologa M, Long D, et al. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol 1989; 160: 1190-4 (Pubitemid 19144484)
21. Schaefer C, Ornoy A, Clementi M, et al. Using observational cohort data for studying drug effects on pregnancy outcome: methodological considerations. Reprod Toxicol 2008; 26: 36-41
22. Rasmussen SA, Mulinare J, Khoury MJ, et al. Evaluation of birth defect histories obtained through maternal interviews. Am J Hum Genet 1990 Mar; 46 (3): 478-85